C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids

C-reactive protein (CRP) is an acute-phase protein that binds specifically to phosphorylcholine (PC) as a component of microbial capsular polysaccharide and participates in the innate immune response against microorganisms. CRP elevation also is a major risk factor for cardiovascular disease. We previously demonstrated that EO6, an antioxidized LDL autoantibody, was a T15 clono-specific anti-PC antibody and specifically binds to PC on oxidized phosphatidylcholine (PtC) but not on native PtC. Similarly, EO6 binds apoptotic cells but not viable cells. In addition, such oxidized phospholipids are recognized by macrophage scavenger receptors, implying that these innate immune responses participate in the clearance because of their proinflammatory properties. We now report that CRP binds to oxidized LDL (OxLDL) and oxidized PtC (OxPtC), but does not bind to native, nonoxidized LDL nor to nonoxidized PtC, and its binding is mediated through the recognition of a PC moiety. Reciprocally, CRP binds to PC, which can be competed for by OxLDL and OxPtC but not by native LDL, nonoxidized PtC, or by oxidized phospholipids without the PC headgroup. CRP also binds to apoptotic cells, and this binding is competed for by OxLDL, OxPtC, and PC. These data suggest that CRP binds OxLDL and apoptotic cells by recognition of a PC moiety that becomes accessible as a result of oxidation of PtC molecule. We propose that, analogous to EO6 and scavenger receptors, CRP is a part of the innate immune response to oxidized PC-bearing phospholipids within OxLDL and on the plasma membranes of apoptotic cells.

[1]  N. Sigal,et al.  The frequency of phosphorylcholine-specific B cells in conventional and germfree BALB/C mice. , 1975, Journal of immunology.

[2]  C. Mold,et al.  Serum Amyloid P Component and C-Reactive Protein Mediate Phagocytosis Through Murine FcγRs1 , 2001, The Journal of Immunology.

[3]  E. Dennis,et al.  The Binding of Oxidized Low Density Lipoprotein to Mouse CD36 Is Mediated in Part by Oxidized Phospholipids That Are Associated with Both the Lipid and Protein Moieties of the Lipoprotein* , 2000, The Journal of Biological Chemistry.

[4]  T. D. Du Clos,et al.  C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. , 1989, Journal of immunology.

[5]  I. Tabas,et al.  Nonoxidative modifications of lipoproteins in atherogenesis. , 1999, Annual review of nutrition.

[6]  J. Volanakis,et al.  Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.

[7]  D. Shih,et al.  Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis* , 2000, The Journal of Biological Chemistry.

[8]  R. Murphy,et al.  Bioactive phospholipid oxidation products. , 2000, Free radical biology & medicine.

[9]  V. Hombach,et al.  C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.

[10]  J. Witztum,et al.  Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. , 1996, The Journal of clinical investigation.

[11]  B. Binder,et al.  Oxidized Membrane Vesicles and Blebs From Apoptotic Cells Contain Biologically Active Oxidized Phospholipids That Induce Monocyte‐Endothelial Interactions , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[12]  N. Brot,et al.  C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response , 2000, The Journal of experimental medicine.

[13]  Charles A. Janeway,et al.  Decoding the Patterns of Self and Nonself by the Innate Immune System , 2002, Science.

[14]  J. Berliner,et al.  Evidence for a role of phospholipid oxidation products in atherogenesis. , 2001, Trends in cardiovascular medicine.

[15]  G. Silverman,et al.  Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. , 2000, The Journal of clinical investigation.

[16]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[17]  K. Wirtz,et al.  Interaction of C-reactive protein with artificial phosphatidylcholine bilayers , 1979, Nature.

[18]  C. Mold,et al.  Regulation of complement activation by C-reactive protein. , 1999, Immunopharmacology.

[19]  D. Steinberg,et al.  Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. , 2001, Journal of lipid research.

[20]  E. Dennis,et al.  Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Kearney Immune recognition of OxLDL in atherosclerosis. , 2000, The Journal of clinical investigation.

[22]  T. D. Du Clos,et al.  Analysis of the binding of C-reactive protein to histones and chromatin. , 1988, Journal of immunology.

[23]  H. Gabbert,et al.  Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[24]  P. Ridker,et al.  Novel clinical markers of vascular wall inflammation. , 2001, Circulation research.

[25]  J L Witztum,et al.  Oxidized phospholipids and isoprostanes in atherosclerosis. , 1998, Current opinion in lipidology.

[26]  M. H. Kaplan,et al.  Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions. , 1961 .

[27]  D. Bharadwaj,et al.  The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II , 1999 .

[28]  E. Dennis,et al.  Correlation of Antiphospholipid Antibody Recognition with the Structure of Synthetic Oxidized Phospholipids , 2002, The Journal of Biological Chemistry.

[29]  E. Dennis,et al.  Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. , 1999, The Journal of clinical investigation.

[30]  T. Kodama,et al.  Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system , 1998, Cellular and Molecular Life Sciences CMLS.

[31]  G. Zimmerman,et al.  Oxidized LDL contains inflammatory PAF-like phospholipids. , 2001, Trends in cardiovascular medicine.

[32]  J. Volanakis,et al.  C‐REACTIVE PROTEIN BINDING SPECIFICITIES: ARTIFICIAL AND NATURAL PHOSPHOLIPID BILAYERS * , 1982, Annals of the New York Academy of Sciences.

[33]  S. Bhakdi,et al.  Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[34]  A. Feinstein,et al.  Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins , 1984, The Journal of experimental medicine.

[35]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[36]  D. Steinberg,et al.  Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Kodama,et al.  Protection from Lethal Gram-Positive Infection by Macrophage Scavenger Receptor–Dependent Phagocytosis , 2000, The Journal of experimental medicine.

[38]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[39]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[40]  R. Terkeltaub,et al.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. , 1996, The Journal of clinical investigation.